An official website of the United States government
Report your review integrity concerns. Report your concerns about unfair review. Learn more about integrity & fairness in review.
Small Business: Cancer Immunotherapy Development – CII (11)
Image
Dr. Asifa Haider
Scientific Review Officer
This special emphasis panel focuses on the many approaches to cellular therapy, including TILs, CAR- and TCR-engineered T cells, NK/NKT cells and their toxicities, as well as therapeutic combinations that employ adoptive and allogeneic cell transfer. It also covers the tumor vaccine development.Review DatesA roster for the panel will be posted here, at least 30 days prior to the review meeting
Topics
- Adoptive cellular therapies (TILs, CAR- and TCR-engineered T cells, NK/NKT cells) using immune cells as cancer treatment and their associated toxicities
- Cellular therapies including dendritic cells and mononuclear phagocytes
- Combination therapies that contain cell therapies
- Tumor vaccines of all types (protein/peptide, viral, DNA/RNA, dendritic cell, tumor cell) and formulations to induce or amplify tumor-specific immunity.
- Preclinical studies of combinations to improve the efficacy of immunotherapies